{"contentid": 488090, "importid": NaN, "name": "Russia\u00e2\u0080\u0099s RDIF partners with Stelis to supply 200 million doses of the Sputnik V vaccine", "introduction": "The Russian Direct Investment Fund (RDIF, Russia\u00e2\u0080\u0099s sovereign wealth fund), and Stelis Biopharma, the biopharmaceutical division of Indian drugmaker Strides Pharma Science, have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against coronavirus sufficient to vaccinate 100 million people.", "content": "<p>The Russian Direct Investment Fund (RDIF, Russia&rsquo;s sovereign wealth fund), and Stelis Biopharma, the biopharmaceutical division of Indian drugmaker Strides Pharma Science (NSE: STAR), have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against coronavirus sufficient to vaccinate 100 million people.</p>\n<p>The agreement between RDIF and Stelis Biopharma was reached under the aegis of Enso Healthcare LLP (part of Enso Group), the RDIF's coordination partner for sourcing Sputnik V vaccines in India.</p>\n<p>The parties intend to commence supplies from the third quarter of 2021. Stelis will also continue to work with the RDIF to provide additional supply volumes beyond the initial agreement.</p>\n<p>RDIF chief executive Kirill Dmitriev commented: &ldquo;We are delighted to announce our agreement with Stelis Biopharma for a significant capacity of Sputnik V. The Russian vaccine with efficacy of 91.6% is one of the best vaccines against coronavirus in the world. The significant vaccine volumes, which will be produced jointly with Stelis, will help to widen access to the vaccine on a global scale.&rdquo;</p>\n<p>Strides founder Arun Kumar added: &ldquo;We are delighted to partner with RDIF to make a substantial contribution towards providing global supply of the Sputnik V vaccine which is one of the most efficacious approved vaccines commercially available. We will also work with RDIF to increase the availability of the vaccine beyond our initial commitments.&rdquo;</p>\n<h2><strong>Sputnik V approved in Philippines</strong></h2>\n<p>Also today, the RDIF separately announced the approval of the Sputnik V vaccine against coronavirus by the Food and Drug Administration (FDA) of the Republic of the Philippines.</p>\n<p>The vaccine was registered under the emergency use authorization procedure. Sputnik V is approved for use in 52 countries with total population of over 1.4 billion people.</p>\n<p>The vaccine had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Bosnia and Herzegovina, Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Republic of the Congo, Djibouti, Sri Lanka, Laos, Iraq, North Macedonia, Kenya, Morocco, Jordan, Namibia and Azerbaijan.</p>", "date": "2021-03-19 11:59:00", "meta_title": "Russia\u00e2\u0080\u0099s RDIF partners with Stelis to supply 200 million doses of the", "meta_keywords": "RDIF, Stelis Biopharma, Strides Pharma, Sputnik V, COVID-19, Vaccine, Production, Approval, Philippines", "meta_description": "Russia\u00e2\u0080\u0099s RDIF partners with Stelis to supply 200 million doses of the Sputnik V vaccine", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-19 11:58:13", "updated": "2021-03-19 12:08:04", "access": NaN, "url": "https://www.thepharmaletter.com/article/russia-s-rdif-partners-with-stelis-to-supply-200-million-doses-of-the-sputnik-v-vaccine", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "vaccine_sputnik_big.jpg", "image2id": "vaccine_sputnik_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "COVID-19 vaccines", "sector_tag": "Pharmaceutical", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Deals, Focus On, Production, Regulation, Russian market", "geography_tag": "Ankleshwa, Gujarat, India, India, Philippines, Russia", "company_tag": "RDIF, Stelis Biopharma, Strides Pharma Science", "drug_tag": "Sputnik V", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-19 11:59:00"}